Balantidiasis is a rare disease caused by bacterial species Balantidium coli. It is a type of intestinal infection commonly observed in pigs. However, cases of human infection have been reported owing to poor hygiene practices, consumption of undercooked pork, and increase in trend of swine farming. The disease is predominant in tropical regions such as Brazil, New Guinea, and southern Iran. Symptoms of the disease include mild to moderate diarrhea, abdominal discomfort, and acute inflammation of the intestine. These are quite similar to symptoms of other intestinal inflammatory conditions such as amoebic dysentery. Balantidium infection can be diagnosed with microscopy and sigmoidoscopy examination. 

Rise in prevalence of balantidiasis infection, surge in the trend of swine farming, increase in research and development activities for the diagnosis of the disease, and rise in awareness about the treatment options are the major factors projected to propel the balantidiasis diagnosis and treatment market during the forecast period. A study conducted by the Stanford University revealed that incidence of the infection have been reported in Bolivia, Papua New Guinea, and the Philippines. The prevalence rate of the balantidiasis infection is lower than 1%. Lower incidence rate in the major pharmaceutical markets such as North America and Europe and competition between already established players are likely to restrain the global balantidiasis diagnosis and treatment market in terms of revenue during the forecast period. 

The global balantidiasis diagnosis and treatment market can be segmented based on diagnosis, product type, end-user, and region. In terms of diagnosis, the market can be classified into microscopy stool examination, sigmoidoscopy, biopsy, and others. Based on product type, the global balantidiasis diagnosis and treatment market can be categorized into tetracycline, iodoquinol, and metronidazole. Tetracycline is the most prescribed drug, with proven efficiency against the bacterial strains of Balantidium coli. In terms of end-user, the balantidiasis diagnosis and treatment market can be divided into hospitals, clinics, and others. 

Based on region, the global balantidiasis diagnosis and treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The disease is less frequently observed among the population in the developed regions such as North America and Europe. However, disease prevalence is significantly higher in the underdeveloped and developing regions such as Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is projected to dominate the global balantidiasis diagnosis and treatment market owing to presence of large population, rise in prevalence of balantidiasis infections, economic growth, and increase in health awareness among the population. Middle East & Africa is anticipated to be second largest market for balantidiasis diagnosis and treatment due to lack of hygiene and sanitation in the rural areas. North America is expected to account for the smallest market share owing to rare occurrence of the disease due to high standards of personal hygiene practices followed by the population. 

Key players operating in the global balantidiasis diagnosis and treatment market include Pfizer, Inc., Abbott, GlaxoSmithKline plc, Novopharm Limited, Physicians Total Care, Inc., Sandoz International GmbH, Amneal Pharmaceuticals LLC., Sanofi, Allergan, and Apotex, Inc.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.